If you have been reading about dual agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Cyclofenil, sold under the brand name Sexovid among others, is a selective estrogen receptor modulator (SERM) medication which is used as a gonadotropin stimulant or ovulation inducer and in menopausal hormone therapy in women. It is mostly no longer available. The medication is taken by mouth. Side effects of cyclofenil include liver toxicity among others. It is a selective estrogen receptor modulator (SERM) and hence is a mixed agonist–antagonist of the estrogen receptor (ER), the biological target of estrogens like estradiol. It has antiestrogenic effects on the hypothalamic–pituitary–gonadal axis and hence can increase sex hormone production and stimulate ovulation. Cyclofenil was introduced for medical use in 1970. It has been mostly discontinued, but remains available in a few countries, including Brazil, Italy, and Japan. It has been used as a doping agent by male athletes.
In the 1960s, Bendix automotive brakes blossomed with the introduction of fixed-caliper disc brakes and the "Duo-Servo" system (which became, virtually, a de facto world standard for drum brakes). During the 1960s, Bendix also dabbled in bicycle hardware, producing a reliable, totally self-contained, 2-speed "Kick-Back" planetary rear axle with coaster braking. Also, just as reliable, was the Bendix "Red Band" and "Red Band II" single speed coaster brake hub. followed by the Bendix "70" and Bendix "80" hub. Considered one of the best hubs on the market, at the time.
=== Neutron source === 252Cf has a number of specialized uses as a strong neutron emitter; it produces 139 million neutrons per microgram per minute. This property makes it useful as a startup neutron source for some nuclear reactors and as a portable (non-reactor based) neutron source for neutron activation analysis to detect trace amounts of elements in samples. Neutrons from californium are used as a treatment of certain cervical and brain cancers where other radiation therapy is ineffective. It has been used in educational applications since 1969 when Georgia Institute of Technology got a loan of 119 μg of 252Cf from the Savannah River Site. It is also used with online elemental coal analyzers and bulk material analyzers in the coal and cement industries. Neutron penetration into materials makes californium useful in detection instruments such as fuel rod scanners; neutron radiography of aircraft and weapons components to detect corrosion, bad welds, cracks and trapped moisture; and in portable metal detectors. Neutron moisture gauges use 252Cf to find water and petroleum layers in oil wells, as a portable neutron source for gold and silver prospecting for on-the-spot analysis, and to detect ground water movement. The main uses of 252Cf in 1982 were, reactor start-up (48.3%), fuel rod scanning (25.3%), and activation analysis (19.4%). By 1994, most 252Cf was used in neutron radiography (77.4%), with fuel rod scanning (12.1%) and reactor start-up (6.9%) as important but secondary uses. In 2021, fast neutrons from 252Cf were used for wireless data transmission.
== Second Ministry == On 9 January 1997, the Governor, Major General Michael Jeffery, designated 17 principal executive offices of the Government under section 43(2) of the Constitution Acts Amendment Act 1899. The following ministers were then appointed to the positions, and served until the reconstitution of the Ministry on 22 December 1999.
from the Miocene strata of the Santalla Formation (Spain), representing the first large vertebrate from the El Bierzo Basin reported to date. A study on deciduous teeth and juvenile skulls of members of the genus Chilotherium, providing evidence of utility of dental characters for species discrimination, is published by Kampouridis et al. (2026). Pandolfi, Codrea & Solomon (2026) describe fossil material of a member of the genus Acerorhinus from the Miocene strata from the Crețești 1 site (Romania), with greatest similarity to A. simplex, and refine the species content of the genus Acerorhinus. Titov et al. (2026) describe fossil material of Elasmotherium chaprovicum from the Pleistocene strata from the Taurida Cave (Crimea), including the first upper milk teeth of a member of the genus Elasmotherium reported to date. Ponomarev et al. (2026) report the discovery of fossil material of Stephanorhinus kirchbergensis in the Pleistocene strata from the Komi Republic (Russia), representing the northernmost record of the species in Europe reported to date. Uzunidis & Pandolfi (2026) report evidence of different dynamics of evolution of body mass of the narrow-nosed rhinoceros from Northern Europe and from the Mediterranean, as well as evidence of consistent mixed-feeding strategy in the studied species, with seasonal specialization toward either browsing or grazing in populations near the end of the temporal range of the species.
Sources: en.wikipedia.org
== Further reading == Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part I. Pathophysiology". Journal of the American Academy of Dermatology. 62 (3): 361–70, quiz 371–2. doi:10.1016/j.jaad.2009.10.042. PMID 20159304. Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part II. Advances and controversies". Journal of the American Academy of Dermatology. 62 (3): 373–84, quiz 385–6. doi:10.1016/j.jaad.2009.10.041. PMID 20159305.
== Five-membered heterocyclic amines == The compound pyrrolidine is composed of molecules that contain a saturated ring of five atoms. This cyclic structure is composed of one atom of nitrogen and four carbon. Nicotine is a molecule containing a pyrrolidine ring attached to a ring of pyridine (other heterocyclic amine). Nicotine belongs to a group of compounds known as alkaloids, which are naturally occurring organic compounds with nitrogen in them. Pyrrole is another compound made up of molecules with a five-membered heterocyclic ring. These molecules are unsaturated and contain a nitrogen atom in the ring. Four pyrrole rings are joined in a ring structure called a porphyrin. The rings of porphyrin are components of hemoglobin, myoglobin, vitamin B12, chlorophyll, and cytochromes. In the centers of heme in hemoglobin, myoglobin, and cytochromes, iron is an ion; in the first two, iron ion is bound to oxygen.
On 8 April 2026, the United States and Iran agreed to a two-week ceasefire in the 2026 Iran war, mediated by Pakistan. Iran had rejected the draft proposal for a 45-day two-phase ceasefire framework introduced on 5 April by Pakistan, instead proposing its own 10-point plan for a peace agreement. The proposal was developed as part of ongoing mediation efforts involving regional and international actors during the 2025–2026 negotiations. Since its declaration, the ceasefire was violated by both sides numerous times. On 21 April, US president Donald Trump extended the ceasefire indefinitely. On 8 July, the ceasefire deal collapsed after attacks by both sides. Low-intensity fighting between the US and Iran continued intermittently. Later, Trump decided to arrive at a more comprehensive ceasefire that would lead to an US–Iranian agreement. As a result, new ceasefire conditions were agreed upon on 12 June. On 17 June, the presidents of both countries signed the Islamabad Memorandum, a memorandum of understanding that formalized the process of ending the war and established a 60-day period to negotiate the final terms of a deal.
==== Angola ==== In August 2023, Lula visited Angola, and met with president João Manuel Lourenço, whom he signed seven cooperation agreements in areas such as agriculture, health and education. During his two-day trip Lula was awarded an order of merit, and paid tribute to Angolan independence wartime statesman António Agostinho Neto. He also said Brazil considers opening a general-consulate in Luanda.
Sources: en.wikipedia.org
Alcohol dehydrogenase class-3 is an enzyme that in humans is encoded by the ADH5 gene. This gene encodes glutathione-dependent formaldehyde dehydrogenase or the class III alcohol dehydrogenase chi subunit, which is a member of the alcohol dehydrogenase family. Members of this family metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products. Class III alcohol dehydrogenase is a homodimer composed of 2 chi subunits. It has virtually no activity for ethanol oxidation, but exhibits high activity for oxidation of long-chain primary alcohols and for oxidation of S-hydroxymethyl-glutathione, a spontaneous adduct between formaldehyde and glutathione. This enzyme is an important component of cellular metabolism for the elimination of formaldehyde, a potent irritant and sensitizing agent that causes lacrymation, rhinitis, pharyngitis, and contact dermatitis.
The isotopes neptunium-235, -236, and -237 are predicted to be fissile; although only neptunium-237's fissionability has been experimentally shown. Its critical mass is about 60 kg, only about 10 kg more than that of the commonly used uranium-235. Calculated values of the critical masses of neptunium-235, -236, and -237 respectively are 66.2 kg, 6.79 kg, and 63.6 kg: the neptunium-236 value is even lower than that of plutonium-239 and 236Np also has a low neutron cross section. However, a neptunium atomic bomb has never been built because uranium and plutonium have lower critical masses than 235Np and 237Np, and 236Np is difficult to purify as it is not found in quantity in spent nuclear fuel and is nearly impossible to separate in any significant quantities from 237Np.
Conveglipron (INNTooltip International Nonproprietary Name; developmental code name HDM1002) is a glucagon-like peptide-1 (GLP-1) receptor agonist which is under development for the treatment of type 2 diabetes, obesity, and diabetes mellitus. It is taken orally. The drug is a small molecule and is a selective and highly potent full agonist of the GLP-1 receptor with antihyperglycemic and antiobesity effects in animals. Conveglipron is under development by Huadong Medicine in China. As of January 2026, it is in phase 3 clinical trials for type 2 diabetes, phase 2 trials for obesity, and phase 1 trials for diabetes mellitus.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.